A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation

Inclusion Criteria:

• Signed informed consent of the subjects or the legal guardian.

• Subjects and guardian are willing and able to cooperate to complete scheduledvisits,treatment plans and laboratory tests and other procedures.

• Diagnosed as chronic kidney disease.

• Glomerular filtration rate (GFR) <75ml/per min/1.73m2.

• After the treatment and adjustment of hypertension, anemia, metabolic acidosis,malnutrition, renal osteopathy, hypothyroidism, etc..

• Chronological age: ≥2years and ≤14years.

• Height Standard Deviation Score(HtSDS) ≤-2SD for chronological age.

• Bone age: girls≤10 years; boys≤11years.

• Pre-pubertal (Tanner Stage I ) patients.

• No history of growth hormone treatment.

Exclusion Criteria:

• Subjects with abnormal liver functions.

• Subjects positive for anti-HBc, HbsAg or HbeAg in Hepatitis B virus tests.

• After adjustment heart function,Cardiac ejection fraction(EF) <50%.

• Subjects with highly allergic constitution or allergy to proteins or investigationalproduct or its excipient.

• Subjects with systemic chronic disease or general infection or mental disease.

• Subjects with diabetes or impaired fasting glucose.

• Subjects with tumor or potential tumor.

• Subjects who are using glucocorticoid or immunosuppressant.

• Other causes for growth retardation.

• Inability to obtain accurate height measurements.

• Subjects who took part in other clinical trials within 3 months.

• Concomitant administration of other treatment that may have an effect on growth within 3 months.

• Other conditions which are unsuitable for this study in the opinion of theinvestigator.